NY-GENERAL-ATLANTIC
9.9.2019 12:02:09 CEST | Business Wire | Press release
Kiwi.com , a leading online travel booking platform powered by cutting-edge technology, today announced a new Board of Directors to guide the Company through its next phase of growth.
Daniel Finnegan, former Chief Financial Officer and Chief Accounting Officer of Booking Holdings (formerly The Priceline Group Inc.), will serve as an independent Board Director. During Mr. Finnegan’s 14-year tenure with Booking Holdings, the company grew to about 22,000 employees and reached a valuation of more than $100 billion.
“I am excited for the opportunity to work with Oliver and the Kiwi team as they build towards ambitious goals that will ultimately provide extraordinary value and experiences to travelers worldwide,” said Daniel Finnegan.
Kiwi.com executives Oliver Dlouhý, Co-founder and CEO, and Juraj Striezenec, CFO, as well as General Atlantic Technology sector team members Tanzeen Syed, Managing Director, and Jessie Cai, Vice President, will also join the Board.
“I am grateful to be surrounded by a group of experts with whom I look forward to closely working as we scale Kiwi.com,” said Oliver Dlouhý. “Our new Board brings a diversity of strategic and operational experience spanning the technology and travel sectors, and Dan’s background as the former CFO of one of the world’s largest travel companies will be invaluable to our business. The creation of this team is an exciting milestone in this next chapter of our growth.”
In June 2019 Kiwi.com announced a strategic investment from General Atlantic , a leading global growth investor, to help scale the business and support management’s vision to create a seamless end-to-end travel experience for customers. General Atlantic has extensive experience in the global online travel industry, with current and past investments including Priceline, Airbnb, Meituan, Flixbus, Uber, Despegar.com, Smiles and Mafengwo.
Tanzeen Syed continued, “We believe the structure and expertise of this Board well-positions Kiwi.com to execute on its vision of creating a comprehensive travel experience for consumers around the globe. The addition of an independent Director of the caliber and experience level of Dan brings further momentum to the business as Kiwi.com enters this next phase of growth. General Atlantic is excited to be working alongside Oliver, the Board and the Kiwi.com team to continue building a next-generation travel technology platform.”
Kiwi.com, a rapidly growing technology company, was founded in 2012 and was recognized as the #1 fastest-growing Czech start-up by Forbes Magazine in 2017 and 2018. Through its proprietary technology and algorithms, Kiwi.com has a unique ability to offer expansive flight options to value-conscious consumers.
The Company pioneered technology that matches passengers to multiple carriers and flights on single itineraries and partners with airlines, online travel agencies, and metasearch engines to sell more than €1 billion in tickets across the globe.
About Kiwi.com
Kiwi.com was founded in 2012 by Oliver Dlouhý and Jozef Képesi. The travel tech company was created for travellers by travellers. Its proprietary algorithm, Virtual Interlining, allows users to combine flights from more than 750 carriers, including many that do not normally cooperate. Kiwi.com also provides its industry-leading Kiwi.com Guarantee, which protects customers from missed connections because of delay, schedule change or cancellation.
Kiwi.com powers more than 100 million flight searches every day and employs over 2,900 people worldwide. It is one of the fastest-growing technology companies in Central Europe. It entered the 2017 Deloitte Technology Fast 500 EMEA list in 7th place, becoming the highest ever ranked Czech company. For the second consecutive year, Kiwi.com was named best Start-up of the Czech Republic by Czech Forbes Magazine in July 2018.
2018 saw the launch of NOMAD, a revolutionary multi-city travel search tool, and Tequila, a B2B platform for partners of all sizes. Also in 2018, Kiwi.com incorporated ground transportation into its search technology.
About General Atlantic
General Atlantic is a leading global growth equity firm providing capital and strategic support for growth companies. Established in 1980, General Atlantic combines a collaborative global approach, sector specific expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to build exceptional businesses worldwide. General Atlantic has more than 150 investment professionals based in New York, Amsterdam, Beijing, Greenwich, Hong Kong, Jakarta, London, Mexico City, Mumbai, Munich, Palo Alto, São Paulo, Shanghai, and Singapore. For more information on General Atlantic, please visit the website: www.generalatlantic.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005279/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom